Skip to main content
. 2011 Apr 8;2(5):381–390. doi: 10.1111/j.2040-1124.2011.00120.x

Figure 1.

image

 Patient disposition. Patients in the P/S group received placebo during the double‐blind period and sitagliptin 50 or 100 mg in the open‐label period. Patients in the S/S group received sitagliptin in both periods. *One patient who discontinued for lack of efficacy at week 50 was included in the efficacy analyses at week 52, thus increasing the group size to 50 patients.